Controversial drug decisions mount as FDA reduces public advisory meetings. Industry leaders say the adcomms can add transparency to the approval process.
WASHINGTON — On Thursday, the Trump administration organized a private press conference so that a senior Food and Drug Administration official could anonymously criticize an experimental Huntington’s disease treatment made by the company UniQure.
In ... [507 chars]